Edarbi: a new angiotensin II antagonist

Edarbi (azilsartan medoxomil) is indicated for the treatment of essential hypertension in adults.

Edarbi: a new option for the management of hypertension
Edarbi: a new option for the management of hypertension

PHARMACOLOGY

Azilsartan medoxomil is an orally active pro-drug. It is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor.1

CLINICAL STUDIES

In a 6-week randomised, double-blind, placebo-controlled trial, azilsartan medoxomil (40mg and 80mg) was compared with valsartan 320mg and olmesartan medoxomil 40mg in 1291 patients. Change from baseline in placebo-adjusted 24-hour mean systolic BP was significantly greater with azilsartan medoxomil 80mg (-14.3mmHg) than olmesartan medoxomil (-11.7mmHg; p=0.009) or valsartan (-10.0mmHg; p<0.001), and the 40mg dose of azilsartan medoxomil was non-inferior to olmesartan (difference -1.4mmHg [95% CI: -3.3 to 0.5]).2

A second 6-week study of similar design involved 1275 patients; 142 received placebo and the remainder received azilsartan medoxomil 20mg, 40mg or 80mg or olmesartan medoxomil 40mg. In this study, the reduction in 24-hour mean systolic BP was 2.1mmHg greater with azilsartan medoxomil 80mg than olmesartan medoxomil 40mg (95% CI -4.0 to -1.0; p=0.038), and azilsartan medoxomil 40mg was non-inferior to olmesartan medoxomil.3

References:

1. Edarbi Summary of Product Characteristics, December 2011.
2. White WB et al. Hypertension 2011; 57: 413-20.
3. Bakris GL et al. J Clin Hypertens 2011; 12: 81-88.

View Edarbi drug record
 
Further information: Takeda UK Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases